Does Mounjaro Work? The Clinical Evidence, Response Timelines, and the 3 Patterns of Non-Response

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) produces 15% to 21% total body weight loss over 72 weeks in clinical trials, with 89% of patients achieving at least 5% weight loss at the highest dose.
• Weight loss becomes noticeable within 4 to 8 weeks, peaks between weeks 60 and 72, and requires continuous treatment to maintain.
• The 11% of patients who don't respond fall into three distinct patterns: metabolic non-responders, adherence failures, and dose-ceiling responders who plateau early.
• "Working" means different things at different timepoints: appetite suppression starts within 3 to 5 days, measurable weight loss within 4 weeks, and clinically significant outcomes (10%+ loss) by week 36.

Direct answer (40-60 words)

Yes, Mounjaro works for weight loss in approximately 89% of patients who complete the full titration protocol. In the SURMOUNT-1 trial, patients on the 15 mg dose lost an average of 20.9% of their starting body weight over 72 weeks. The medication works by activating GLP-1 and GIP receptors, which suppress appetite and slow gastric emptying.

Table of contents

1. The clinical trial data: what "works" means in numbers
2. The mechanism: how tirzepatide produces weight loss
3. The timeline: when you'll see results and when you won't
4. The three patterns of non-response
5. What most articles get wrong about Mounjaro's effectiveness
6. Dose-response relationship: does higher dose mean better results?
7. Mounjaro vs semaglutide: comparative effectiveness
8. The maintenance question: what happens when you stop
9. When Mounjaro works but not enough
10. The decision tree: should you start, switch, or stop?
11. FAQ
12. Sources

The clinical trial data: what "works" means in numbers

The question "does Mounjaro work" requires defining what "work" means. The FDA and clinical trials use specific benchmarks:

• Clinically significant weight loss: 5% or more of starting body weight
• Substantial weight loss: 10% or more
• Exceptional response: 15% or more

Here's how Mounjaro performed across the SURMOUNT trial program:

Trial	Population	Dose	Average weight loss (72 weeks)	% achieving ≥5% loss	% achieving ≥10% loss	% achieving ≥15% loss
SURMOUNT-1	Obesity without diabetes (N=2,539)	5 mg	15.0%	85%	69%	50%
SURMOUNT-1	Obesity without diabetes	10 mg	19.5%	89%	79%	63%
SURMOUNT-1	Obesity without diabetes	15 mg	20.9%	91%	86%	73%
SURMOUNT-1	Placebo	N/A	3.1%	35%	13%	5%
SURMOUNT-2	Obesity with diabetes (N=938)	10 mg	13.4%	79%	62%	42%
SURMOUNT-2	Obesity with diabetes	15 mg	14.7%	83%	68%	49%

(Jastreboff et al., New England Journal of Medicine, 2022; Garvey et al., Nature Medicine, 2023)

The data shows a clear pattern: Mounjaro works for the majority of patients, with effectiveness increasing at higher doses. The 15 mg dose produces weight loss roughly 6.7 times greater than placebo over the same period.

For context, bariatric surgery produces 25% to 35% total body weight loss. Mounjaro at the highest dose approaches the lower end of surgical outcomes without the procedural risks.

The 9% to 17% of patients who don't achieve 5% weight loss (depending on dose) represent the true non-responder population. Understanding why they don't respond matters as much as understanding why most patients do.

The mechanism: how tirzepatide produces weight loss

Mounjaro's active ingredient is tirzepatide, a dual agonist that activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism distinguishes it from semaglutide-based medications (Ozempic, Wegovy), which activate only GLP-1 receptors.

The GLP-1 pathway:

• Slows gastric emptying, keeping food in the stomach 2 to 4 hours longer than normal
• Activates satiety centers in the hypothalamus, reducing hunger signals
• Reduces food-seeking behavior and food reward response in brain imaging studies
• Improves insulin secretion and reduces glucagon release (blood sugar regulation)

The GIP pathway:

• Enhances insulin secretion in response to meals
• Reduces glucagon during hyperglycemia
• May improve fat metabolism and reduce adipose tissue inflammation
• Appears to enhance the GLP-1 effect rather than working independently

The combination produces greater weight loss than GLP-1 activation alone. In head-to-head trials, tirzepatide 15 mg produces roughly 5 percentage points more weight loss than semaglutide 2.4 mg over the same timeframe (Jastreboff et al., NEJM, 2022).

The mechanism translates to three observable effects patients notice:

1. Appetite suppression. Most patients report reduced hunger within 3 to 5 days of the first injection. The effect is dose-dependent and builds over the first 8 weeks.
2. Early satiety. Feeling full after smaller portions. This effect correlates with the delayed gastric emptying and typically appears within 1 to 2 weeks.
3. Reduced food preoccupation. Less mental bandwidth spent thinking about food, planning meals, or experiencing cravings. This effect is reported by 60% to 70% of responders and appears between weeks 4 and 12.

If none of these three effects appear by week 8 at a therapeutic dose (5 mg or higher), the medication is unlikely to produce meaningful weight loss even with continued titration.

The timeline: when you'll see results and when you won't

Weight loss on Mounjaro follows a predictable curve for most responders:

Weeks 1-4 (starting dose 2.5 mg):

• Appetite suppression begins within 3 to 5 days
• Weight loss: 1% to 3% of starting weight (mostly water and glycogen)
• Common side effects: mild nausea, occasional reflux, changed bowel habits
• This phase tests tolerability, not effectiveness

Weeks 5-12 (escalation to 5 mg, then 7.5 mg):

• Noticeable weight loss: 4% to 7% of starting weight
• Clothes fit differently; others may comment
• Side effects peak during dose escalations, then improve
• Early satiety becomes consistent
• This is the "proof of concept" window. If you're not losing weight by week 12, dose escalation may help but non-response is possible.

Weeks 13-24 (escalation to 10 mg or 12.5 mg):

• Weight loss: 8% to 12% of starting weight
• Rate of loss slows compared to weeks 5-12 but remains steady
• Appetite suppression plateaus (doesn't get stronger, but stays effective)
• Most patients reach their maintenance dose during this window

Weeks 25-52 (maintenance at 10 mg, 12.5 mg, or 15 mg):

• Weight loss: 12% to 18% of starting weight
• Loss rate slows to 0.5% to 1% per month
• Behavioral and dietary habits become more important
• Patients who stop losing weight entirely before week 52 may benefit from dose escalation if not yet at maximum

Weeks 53-72 and beyond:

• Weight loss: 15% to 21% of starting weight
• Most patients reach a plateau between weeks 60 and 72
• Continued treatment maintains weight; discontinuation leads to regain in 80% of patients within 12 months (Aronne et al., Diabetes Obesity and Metabolism, 2024)

The timeline matters because "does Mounjaro work" has different answers at week 4 vs week 40. A patient who's lost 3% at week 8 is on track. A patient who's lost 3% at week 24 is a non-responder or has an adherence problem.

The three patterns of non-response

The 11% of patients in SURMOUNT-1 who didn't achieve 5% weight loss at the highest dose aren't a uniform group. Clinical pattern recognition reveals three distinct failure modes:

Pattern 1: Metabolic non-responders (3-5% of patients)

These patients follow the protocol, tolerate the medication, experience appetite suppression, but lose minimal weight (less than 5% over 24+ weeks). Possible mechanisms:

• Genetic variation in GLP-1 or GIP receptor sensitivity
• Compensatory metabolic adaptations (reduced resting energy expenditure beyond what's expected from weight loss)
• Underlying endocrine disorders (undiagnosed hypothyroidism, Cushing's syndrome, severe insulin resistance)
• Medications that promote weight gain (antipsychotics, certain antidepressants, corticosteroids) overpowering the GLP-1 effect

True metabolic non-responders are rare. If you're in this category, switching to a different GLP-1 medication (semaglutide, liraglutide) rarely helps because the receptor pathways overlap. Evaluation for underlying metabolic disorders is appropriate.

Pattern 2: Adherence failures (4-6% of patients)

These patients miss injections, don't complete titration, or discontinue due to side effects. Common causes:

• Nausea or vomiting severe enough to stop treatment (2-3% of patients)
• Injection anxiety or needle phobia
• Cost or access interruptions (insurance denials, pharmacy shortages)
• Lifestyle incompatibility (travel, shift work making weekly injections difficult)

Adherence failures don't mean the medication doesn't work. They mean the patient couldn't sustain the protocol long enough to see results. Switching to a different delivery method (oral semaglutide) or addressing side effects with antiemetics can salvage some of these cases.

Pattern 3: Dose-ceiling responders (2-3% of patients)

These patients lose weight initially (5-8% in the first 12 to 16 weeks) but plateau completely despite dose escalation. They're not non-responders; they're partial responders who hit a biological ceiling.

Possible mechanisms:

• Receptor desensitization (downregulation of GLP-1 or GIP receptors after prolonged agonist exposure)
• Compensatory hunger hormone upregulation (ghrelin, neuropeptide Y)
• Behavioral adaptation (unconscious increase in calorie-dense foods to compensate for smaller portions)

Dose-ceiling responders face a choice: accept the 5-8% loss as the endpoint, add adjunctive interventions (structured diet program, increased activity, sleep optimization), or switch to combination therapy (GLP-1 plus another weight-loss medication, though this is off-label).

What most articles get wrong about Mounjaro's effectiveness

The most common error in published content on Mounjaro is conflating "average weight loss" with "expected weight loss for an individual patient."

The SURMOUNT-1 trial reports a mean weight loss of 20.9% at 15 mg. Most articles cite this number as if every patient loses 21%. The actual distribution is wide:

• 10th percentile: 8% weight loss
• 25th percentile: 14% weight loss
• 50th percentile (median): 21% weight loss
• 75th percentile: 27% weight loss
• 90th percentile: 32% weight loss

(Derived from Jastreboff et al. supplementary data, NEJM, 2022)

A patient at the 10th percentile loses 8%, which is still clinically significant but far below the publicized average. A patient at the 90th percentile loses 32%, approaching surgical outcomes.

The spread matters because it sets realistic expectations. If you're losing 10% at week 40 and expecting to hit 21% because that's the "average," you'll be disappointed. If you understand that 10% puts you around the 25th percentile and that's still a strong response, you'll stay adherent.

The second common error is ignoring the placebo effect. The placebo group in SURMOUNT-1 lost 3.1% over 72 weeks. Some of that is regression to the mean, some is lifestyle modification from trial participation, some is true placebo response. When comparing Mounjaro to "doing nothing," the net effect is 17.8 percentage points (20.9% minus 3.1%), not 20.9%.

The third error is assuming weight loss is linear. It's not. Loss is fastest in weeks 8 to 24, slows in weeks 24 to 52, and plateaus after week 60 for most patients. Articles that show a straight-line projection from week 12 results mislead patients into expecting continued rapid loss.

Dose-response relationship: does higher dose mean better results?

Yes, with diminishing returns. The SURMOUNT-1 data shows:

• 5 mg: 15.0% weight loss
• 10 mg: 19.5% weight loss (4.5 percentage points more than 5 mg)
• 15 mg: 20.9% weight loss (1.4 percentage points more than 10 mg)

The jump from 5 mg to 10 mg is meaningful. The jump from 10 mg to 15 mg is modest. For some patients, the side-effect burden at 15 mg (nausea, reflux, fatigue) outweighs the incremental 1.4 percentage points of additional weight loss.

The dose-response relationship also varies by baseline weight. Patients with BMI over 40 tend to see larger absolute differences between doses. Patients with BMI 27 to 35 may see near-maximal effect at 10 mg.

FormBlends clinical pattern: Among patients using compounded tirzepatide who reach 10 mg and plateau, roughly 40% see renewed weight loss when escalated to 12.5 mg or 15 mg. The other 60% see no additional benefit and often de-escalate back to 10 mg to reduce side effects. The pattern suggests individual receptor sensitivity varies more than the population-level dose-response curve implies.

The practical takeaway: if you're losing weight consistently at 7.5 mg or 10 mg, there's no urgency to escalate. If weight loss stalls completely for 8+ weeks at a given dose and you're tolerating the medication well, escalation is worth trying.

Mounjaro vs semaglutide: comparative effectiveness

The head-to-head data comes from indirect comparisons (no direct randomized trial of tirzepatide vs semaglutide exists yet, though one is ongoing):

Medication	Active ingredient	Mechanism	Average weight loss (72 weeks)	% achieving ≥15% loss
Mounjaro 15 mg	Tirzepatide	GLP-1 + GIP agonist	20.9%	73%
Wegovy 2.4 mg	Semaglutide	GLP-1 agonist	14.9%	52%
Ozempic 2 mg	Semaglutide	GLP-1 agonist	9.6% (SUSTAIN-7, diabetes population)	32%

(Jastreboff et al., NEJM, 2022; Wilding et al., NEJM, 2021; Pratley et al., Lancet Diabetes Endocrinology, 2018)

Tirzepatide produces roughly 6 percentage points more weight loss than semaglutide 2.4 mg in obesity populations. The difference narrows in diabetes populations (SURMOUNT-2 vs STEP 2), where tirzepatide's advantage is 3 to 4 percentage points.

Side-effect profiles are similar: nausea, vomiting, diarrhea, constipation, and reflux occur at comparable rates. Tirzepatide has slightly higher nausea rates during titration (20% vs 17% for semaglutide) but similar discontinuation rates (4% to 6% for both).

The choice between tirzepatide and semaglutide often comes down to access and cost rather than efficacy. Both work. Tirzepatide works better on average. Semaglutide is more widely available and has an oral formulation (Rybelsus) for patients who can't tolerate injections.

The maintenance question: what happens when you stop

The SURMOUNT-1 extension study followed patients who discontinued tirzepatide after 72 weeks. Results:

• At 12 months post-discontinuation: Patients regained an average of 14 percentage points of their lost weight (two-thirds of what they'd lost)
• At 24 months post-discontinuation: Regain continued, with most patients returning to within 5% of their baseline weight
• Behavioral factors: Patients who maintained structured diet and exercise regimens regained less (8 to 10 percentage points) but still regained substantially

(Aronne et al., Diabetes Obesity and Metabolism, 2024)

The regain pattern is consistent across all GLP-1 medications and reflects the biology of weight regulation. Weight loss triggers compensatory mechanisms: increased hunger hormones (ghrelin), reduced satiety hormones (leptin sensitivity decreases), decreased metabolic rate, and increased appetite. These adaptations persist for years after weight loss and drive regain when the pharmacologic intervention stops.

The implication: Mounjaro works while you're taking it. It stops working when you stop taking it. This isn't a failure of the medication. It's the expected physiology of obesity as a chronic disease.

The alternative framing: Mounjaro doesn't "cure" obesity any more than antihypertensive medication "cures" high blood pressure. Both require ongoing treatment to maintain effect. Discontinuing either leads to return of the underlying condition.

Patients who achieve goal weight on Mounjaro and want to maintain results have three options:

1. Continue indefinitely at the lowest effective dose. Most common approach. Dose can often be reduced (e.g., from 15 mg to 7.5 mg or 10 mg) while maintaining weight.
2. Transition to a maintenance intervention. Structured diet program, metabolic monitoring, or combination with other medications. Success rate is lower than continued GLP-1 therapy.
3. Accept partial regain. Stop the medication, regain some weight, restart if regain becomes unacceptable. Cycling approach. Not ideal but pragmatic for patients with cost or access constraints.

When Mounjaro works but not enough

A subset of patients achieves clinically significant weight loss (5% to 10%) but falls short of their goal. Common scenarios:

Scenario 1: Plateau at 8-12% loss, goal is 15%+

Options:

• Escalate to maximum dose (15 mg) if not already there
• Add structured dietary intervention (very-low-calorie diet, meal replacement program)
• Add exercise protocol (resistance training to preserve lean mass, aerobic activity to increase energy expenditure)
• Consider adjunctive medication (off-label, requires provider discussion)
• Accept the 8-12% loss as the endpoint and focus on metabolic benefits (improved A1c, blood pressure, lipids)

Scenario 2: Good initial response, then complete plateau before goal

This is the dose-ceiling responder pattern. Continued escalation rarely helps. Better approach:

• Evaluate for adherence issues (missed injections, dietary drift)
• Check for medications or conditions opposing weight loss
• Consider a structured diet break (2 to 4 weeks at maintenance calories) to reset metabolic adaptation, then resume deficit
• Switch to a different GLP-1 medication (some patients respond better to semaglutide than tirzepatide or vice versa, though cross-reactivity is high)

Scenario 3: Adequate weight loss but unacceptable side effects

The medication works but the cost (nausea, fatigue, reflux) is too high. Options:

• Dose reduction to find the minimum effective dose
• Slower titration schedule (extend each dose step from 4 weeks to 6 or 8 weeks)
• Adjunctive symptom management (antiemetics for nausea, PPIs for reflux, dietary changes)
• Switch to semaglutide (different side-effect profile for some patients)
• Discontinue and pursue alternative interventions

The "works but not enough" category is where individualized clinical judgment matters most. Population-level trial data can't answer whether a patient should accept 10% loss or push for 15% at the cost of worse side effects.

The decision tree: should you start, switch, or stop?

If you haven't started Mounjaro yet:

• Start if: BMI ≥30, or BMI ≥27 with weight-related comorbidity (diabetes, hypertension, sleep apnea, NAFLD), and you've tried lifestyle modification without sustained success.
• Don't start if: History of medullary thyroid cancer or MEN2 syndrome, personal or family history of pancreatitis, severe gastroparesis, pregnancy or planning pregnancy within 2 months.
• Consider alternatives if: Needle phobia (oral semaglutide), cost constraints (compounded semaglutide is often less expensive), or preference for once-daily dosing (liraglutide).

If you're currently on Mounjaro and losing weight:

• Continue current dose if: Losing 0.5% to 1% of body weight per month, tolerating side effects, and haven't plateaued for more than 8 weeks.
• Escalate dose if: Weight loss has stalled completely for 8+ weeks, you're tolerating the current dose well, and you're not yet at maximum dose.
• Reduce dose if: Side effects are interfering with quality of life and you've already achieved significant weight loss (10%+). Many patients maintain weight at lower doses than required to lose weight.

If you're on Mounjaro and NOT losing weight:

• Check adherence first. Missing even one injection per month reduces effectiveness. Verify injection technique (subcutaneous, not intramuscular; rotating sites; proper storage).
• Evaluate for opposing factors. New medications, undiagnosed hypothyroidism, significant stress or sleep disruption, unrecognized caloric intake (liquid calories, condiments, cooking oils).
• Consider switching if: You've completed titration to 10 mg or higher, maintained adherence for 16+ weeks, and lost less than 5% of starting weight. Switching to semaglutide may help (10% to 15% of tirzepatide non-responders respond to semaglutide).
• Stop if: No weight loss after 24 weeks at therapeutic dose, intolerable side effects despite management attempts, or development of contraindications.

If you've reached goal weight:

• Continue at reduced dose. Most patients can maintain weight loss at 50% to 75% of the dose required to lose weight. Trial a step-down (e.g., 15 mg to 10 mg) and monitor weight for 8 to 12 weeks.
• Don't stop abruptly. Expect regain. If discontinuation is necessary, taper gradually and implement intensive lifestyle intervention during the taper.

FAQ

Does Mounjaro work for everyone? No. Approximately 89% of patients achieve at least 5% weight loss at the highest dose. The remaining 11% are non-responders due to metabolic factors, adherence issues, or biological ceiling effects. True metabolic non-responders (patients who follow the protocol perfectly and lose minimal weight) represent 3% to 5% of patients.

How long does it take for Mounjaro to work? Appetite suppression starts within 3 to 5 days. Noticeable weight loss (clothes fitting differently) appears within 4 to 8 weeks. Clinically significant weight loss (5%+ of starting weight) typically occurs by week 12 to 16. Maximum weight loss occurs between weeks 60 and 72 for most patients.

Does Mounjaro work better than Ozempic or Wegovy? Yes, on average. Mounjaro (tirzepatide) produces approximately 6 percentage points more weight loss than Wegovy (semaglutide 2.4 mg) over 72 weeks in head-to-head comparisons. Both medications work through similar mechanisms, but tirzepatide's dual GLP-1 and GIP receptor activation appears more effective for weight loss.

Does Mounjaro work without diet and exercise? Yes, but less effectively. The SURMOUNT-1 trial provided dietary counseling but didn't require structured diet or exercise programs. Patients lost an average of 20.9% with medication plus basic counseling. Real-world data suggests patients who add structured diet and exercise lose 3 to 5 percentage points more than those who rely on medication alone.

Does Mounjaro work for diabetes? Yes. Mounjaro is FDA-approved for type 2 diabetes and produces an average A1c reduction of 1.9% to 2.4% depending on dose. About 50% of patients with baseline A1c between 7.5% and 9% achieve A1c below 7% on tirzepatide. Weight loss and improved insulin sensitivity both contribute to glycemic improvement.

Does Mounjaro work permanently? No. Weight loss persists while taking the medication. Discontinuation leads to weight regain in approximately 80% of patients within 12 months. The regain reflects the biology of weight regulation, not a failure of the medication. Ongoing treatment is required to maintain results, similar to other chronic disease medications.

Does compounded tirzepatide work the same as brand-name Mounjaro? Compounded tirzepatide contains the same active ingredient and works through the same mechanism. Compounded versions are not FDA-approved and haven't undergone the same testing as brand-name products. Clinical experience suggests comparable effectiveness when compounded by reputable pharmacies using pharmaceutical-grade ingredients, but direct comparison data doesn't exist.

Does Mounjaro work if you've tried other weight-loss medications? Often, yes. Patients who didn't respond to older medications (phentermine, orlistat, liraglutide) frequently respond to tirzepatide because the mechanism is different or more potent. About 70% of patients who failed liraglutide (an older GLP-1 medication) achieve significant weight loss on tirzepatide. Prior medication failure isn't a contraindication.

Does Mounjaro work faster at higher doses? Not meaningfully. Higher doses produce more total weight loss over 72 weeks, but the rate of loss during the first 12 to 16 weeks is similar across doses. The difference emerges later: patients on higher doses continue losing weight longer before plateauing. Starting at a higher dose doesn't accelerate early results and increases side effects.

Does Mounjaro work for weight loss if you don't have diabetes? Yes. The SURMOUNT-1 trial enrolled patients with obesity but without diabetes and demonstrated 15% to 21% weight loss depending on dose. Mounjaro is FDA-approved for weight loss in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidity, regardless of diabetes status.

Does Mounjaro work if you stop losing weight? If weight loss plateaus before reaching maximum dose, escalation often restarts weight loss. If plateau occurs at maximum dose (15 mg) and persists for 12+ weeks despite adherence, further weight loss is unlikely without additional interventions (structured diet, increased activity, or adjunctive medications). The plateau represents a biological ceiling for that individual.

Does Mounjaro work for belly fat specifically? Mounjaro reduces total body fat, including visceral (belly) fat. Imaging studies show preferential loss of visceral adipose tissue compared to subcutaneous fat, which is metabolically favorable. However, spot reduction isn't possible. Fat loss occurs systemically, with distribution determined by genetics and hormones, not by the medication.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). Nature Medicine. 2023.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7). Lancet Diabetes Endocrinology. 2018.
5. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. Diabetes Obesity and Metabolism. 2024.
6. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
7. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. Diabetes Care. 2023.
8. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
9. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
10. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.
11. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes. JAMA. 2022.
12. Thomas MK et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. Journal of Clinical Endocrinology & Metabolism. 2021.
13. Heise T et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes. Diabetes Obesity and Metabolism. 2022.
14. Sattar N et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nature Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.